Kiora Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Kiora Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.6 times its market value (net cash). Higher than 94% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 1,785% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 91% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-60.6×Operating cash was negative last year, while some debt falls due within a year.
Lower than 76% of Healthcare companies in United States.
Cash Cushion Ratio
1.6× cashCash, after subtracting all debt, is 1.6 times its market value (net cash).
Higher than 94% of Healthcare companies in United States.
Tangible Assets Ratio
91%Of every $100 the company owns, $91 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 64% of Healthcare companies in United States.
Tangible Net Worth Ratio
87%Of every $100 of net worth, $87 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 68% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Kiora Pharmaceuticals, Inc. made a loss over the last year. Kiora Pharmaceuticals, Inc. owes $0.29 for every $1 it owns. Kiora Pharmaceuticals, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossKiora Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.61The share price is 0.61 times Kiora Pharmaceuticals, Inc.'s book value per share, lower than 88% of Healthcare companies in United States.
Market cap
$10 MThe total market value of all of Kiora Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), smaller than 87% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$17 MWhat Kiora Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.81Net worth divided by the number of shares. The share price of $2.32 is 0.6 times this, which is the P/B above.
Return on equity (ROE)
-56.4%Kiora Pharmaceuticals, Inc. lost 56.4% of its shareholders' money over the last year, lower than 55% of Healthcare companies in United States.
Owes vs Owns
0.29×Kiora Pharmaceuticals, Inc. owes $0.29 for every $1 it owns (low), lower than 61% of Healthcare companies in United States.
Dividend yield
NoneKiora Pharmaceuticals, Inc. does not currently pay a dividend.
Profit growth
LossKiora Pharmaceuticals, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Interest cover
Not coveredKiora Pharmaceuticals, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashKiora Pharmaceuticals, Inc. held $17 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Kiora Pharmaceuticals, Inc.: $10 M ÷ $17 M (30 Jun 2026) = 0.6.
What is Kiora Pharmaceuticals, Inc.'s return on equity?
Kiora Pharmaceuticals, Inc. lost 56.4% of its shareholders' money over the last year, lower than 55% of Healthcare companies in United States.
How much does Kiora Pharmaceuticals, Inc. owe compared with what it owns?
Kiora Pharmaceuticals, Inc. owes $0.29 for every $1 it owns (low), lower than 61% of Healthcare companies in United States.
Does Kiora Pharmaceuticals, Inc. pay a dividend?
No. Kiora Pharmaceuticals, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.